Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
microbiome targeted therapies for primary sclerosing cholangitis
Original title: “Microbiome Targeted Therapies for Primary Sclerosing Cholangitis.”
phenotype and prognosis of primary sclerosing cholangitis autoimmune hepatitis variant syndrome
Original title: “Phenotype and prognosis of primary sclerosing cholangitis-autoimmune hepatitis variant syndrome.”
CSL will co-develop and co-promote Alentis Therapeutics' anti-claudin-1 therapy lixudebart for kidney and liver conditions, including primary sclerosing cholangitis and a systemic autoimmune disease characterized by small blood vessel inflammation.
Original title: “CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential”
psc dm a validated clinical diagnostic model for distinguishing primary from secondary sclerosing cholangitis
Original title: “PSC-DM: A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis.”
ep547 mrgprx4 inverse agonist for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis results from the phase 2 randomized placebo controlled pacific study
Original title: “EP547 (MRGPRX4 inverse agonist) for cholestatic pruritus due to primary biliary cholangitis or primary sclerosing cholangitis: Results from the phase 2 randomized, placebo-controlled PACIFIC study.”
gut microbiota derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling
Original title: “Gut microbiota-derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling.”
from cholestasis to interface hepatitis a rare case of primary sclerosing cholangitis autoimmune hepatitis overlap in a 20 year old male
Original title: “"From Cholestasis to Interface Hepatitis: A Rare Case of Primary Sclerosing Cholangitis-Autoimmune Hepatitis Overlap in a 20-Year-Old Male".”
prognostic performance of liver stiffness measurements in primary sclerosing cholangitis the prospective ficus cohort
Original title: “Prognostic performance of liver stiffness measurements in primary sclerosing cholangitis: the prospective FICUS cohort.”
author s reply fibrate therapy in primary sclerosing cholangitis
Original title: “Author's reply: "Fibrate therapy in primary sclerosing cholangitis".”
salvage tacrolimus therapy for steroid refractory immune related adverse event associated sclerosing cholangitis
Original title: “Salvage tacrolimus therapy for steroid-refractory immune-related adverse event-associated sclerosing cholangitis.”
quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis
Original title: “Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.”
long term add on fibrate therapy in primary sclerosing cholangitis safety biochemical response and disease progression
Original title: “Long-term add-on fibrate therapy in Primary Sclerosing Cholangitis: Safety, biochemical response, and disease progression.”
prognostic value of magnetic resonance imaging in pediatric onset primary sclerosing cholangitis
Original title: “Prognostic value of magnetic resonance imaging in pediatric-onset primary sclerosing cholangitis.”
oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease paving a path forward
Original title: “Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease - paving a path forward.”
proteome scale autoantibody profiling in psc associations with clinical phenotypes and evidence for neuroendocrine deregulations
Original title: “Proteome-scale autoantibody profiling in PSC: Associations with clinical phenotypes and evidence for neuroendocrine deregulations.”